Poxel SA

Follow-on public offerings (FOPOs) have become increasingly difficult to execute in the current financial market climate with public biopharmaceutical company valuations plummeting, so many drug devel

Poxel SA is seeking more Asian marketing deals for its Sumitomo Pharma Co., Ltd. -partnered first-in-class anti-diabetic product Twymeeg in a bid to pay off its debt and enhance its dwindling cash p

Cash-poor Poxel SA is drawing nearer to a key decision about which of its two mid-stage non-alcoholic steatohepatitis candidates to move into Phase III, but positive top-line data reported on 30 Aug

In the past, the regulatory approval of a drug was directly associated with commercial success. But drug pricing issues, different markets’ regulatory requirements and payers’ reimbursement stringency